Medicaid Provider Spending

$1.09 trillion in Medicaid claims data, 2018–2024 · 617K+ providers

CALDWELL MEMORIAL HOSPITAL INC

NPI: 1134126659 · COLUMBIA, LA 71418 · Rehabilitation Hospital Unit · NPI assigned 06/30/2005

$525K
Total Medicaid Paid
58,764
Total Claims
46,602
Beneficiaries
45
Codes Billed
2018-01
First Month
2024-12
Last Month

Provider Details

Authorized OfficialETHERIDGE, RHONDA (OFFICE MANAGER)
NPI Enumeration Date06/30/2005

Related Entities

Other providers sharing the same authorized official: ETHERIDGE, RHONDA

ProviderCityStateTotal Paid
CALDWELL MEMORIAL HOSPITAL INC COLUMBIA LA $8.20M
CALDWELL MEMORIAL HOSPITAL, INC. WISNER LA $3.18M
CALDWELL MEMORIAL HOSPITAL, INC CHATHAM LA $1.49M
CALDWELL MEMORIAL HOSPITAL, INC. COLUMBIA LA $184K

Monthly Spending Trend

Yearly Breakdown

YearClaimsTotal Paid
2018 9,467 $78K
2019 9,369 $76K
2020 6,307 $59K
2021 8,117 $99K
2022 9,386 $105K
2023 9,401 $68K
2024 6,717 $40K

Billing Codes

CodeDescriptionClaimsBeneficiariesTotal Paid
80053 Comprehensive metabolic panel 10,402 8,546 $75K
0223U 156 129 $52K
71046 Radiologic examination, chest; 2 views 1,444 1,183 $49K
85027 8,778 7,088 $38K
87502 Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets 824 632 $36K
87637 Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV 274 228 $31K
36415 Collection of venous blood by venipuncture 14,651 11,486 $29K
83880 1,575 1,169 $26K
87811 Infectious agent antigen detection by immunoassay; SARS-CoV-2 (COVID-19) 703 642 $20K
87880 Infectious agent antigen detection by immunoassay; Streptococcus, group A 1,309 1,079 $16K
83735 4,526 3,482 $15K
80061 Lipid panel 1,547 1,341 $14K
85025 Blood count; complete (CBC), automated, and automated differential WBC count 3,048 2,239 $13K
83036 Hemoglobin; glycosylated (A1C) 2,539 2,137 $13K
87798 Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism 551 231 $12K
93005 Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report 341 306 $11K
87635 Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe 217 196 $9K
86328 228 195 $8K
87486 281 231 $8K
87581 281 231 $8K
72110 217 189 $7K
0202U Oncology (prostate), multianalyte, gene expression profiling 14 14 $5K
84443 Thyroid stimulating hormone (TSH) 565 462 $5K
87633 Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets 18 12 $5K
87081 561 482 $3K
80305 276 223 $2K
81003 1,355 930 $2K
82306 Vitamin D; 25 hydroxy, includes fraction(s), if performed 162 142 $2K
U0003 Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r 21 21 $1K
80048 Basic metabolic panel (calcium, ionized) 428 264 $1K
87804 Infectious agent antigen detection by immunoassay; Influenza, each type 114 39 $1K
87651 Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe 120 105 $1K
73562 65 39 $952.98
87634 28 25 $912.60
80307 Drug test(s), presumptive, any number of drug classes; immunoassay 19 15 $807.82
86308 151 123 $786.49
73565 51 41 $762.75
81001 185 171 $643.27
84439 135 105 $451.00
84484 28 26 $236.93
84155 21 18 $44.04
86140 17 12 $36.26
85651 17 12 $29.89
C9803 Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source 13 12 $0.00
G0481 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed 508 349 $0.00